175 related articles for article (PubMed ID: 8020835)
1. Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer.
Malmström H; Carstensen J; Simonsen E
Gynecol Oncol; 1994 Jul; 54(1):27-34. PubMed ID: 8020835
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal chemotherapy in peritoneal malignancy: impact of intensive system care on practicability.
Knüsli C; Ruff P; Laffer U; Stoll HR; Obrist R; Weber W; Obrecht JP
Acta Med Austriaca; 1989; 16(3-4):70-3. PubMed ID: 2692376
[TBL] [Abstract][Full Text] [Related]
3. Problems associated with the administration of intraperitoneal therapy using the Port-A-Cath system.
Almadrones L; Yerys C
Oncol Nurs Forum; 1990; 17(1):75-80. PubMed ID: 2300507
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
Landrum LM; Gold MA; Moore KN; Myers TK; McMeekin DS; Walker JL
Gynecol Oncol; 2008 Feb; 108(2):342-7. PubMed ID: 17988721
[TBL] [Abstract][Full Text] [Related]
5. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
[TBL] [Abstract][Full Text] [Related]
6. Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis.
Emoto S; Ishigami H; Hidemura A; Yamaguchi H; Yamashita H; Kitayama J; Watanabe T
Jpn J Clin Oncol; 2012 Nov; 42(11):1013-9. PubMed ID: 22872745
[TBL] [Abstract][Full Text] [Related]
7. Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma.
Sakuragi N; Nakajima A; Nomura E; Noro N; Yamada H; Yamamoto R; Fujimoto S
Gynecol Oncol; 2000 Dec; 79(3):420-3. PubMed ID: 11104613
[TBL] [Abstract][Full Text] [Related]
8. Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience.
Ivy JJ; Geller M; Pierson SM; Jonson AL; Argenta PA
Gynecol Oncol; 2009 Sep; 114(3):420-3. PubMed ID: 19560189
[TBL] [Abstract][Full Text] [Related]
9. Complications associated with intraperitoneal chemotherapy catheters.
Makhija S; Leitao M; Sabbatini P; Bellin N; Almadrones L; Leon L; Spriggs DR; Barakat R
Gynecol Oncol; 2001 Apr; 81(1):77-81. PubMed ID: 11277654
[TBL] [Abstract][Full Text] [Related]
10. Therapy of infections related to intraperitoneal catheters in patients with ovarian cancer.
Meunier F; van der Auwera P; Aoun M; Piccart M; Sculier JP
Scand J Infect Dis Suppl; 1990; 72():26-8. PubMed ID: 2151063
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients.
Malmström H; Simonsen E; Westberg R
Gynecol Oncol; 1994 Jan; 52(1):20-5. PubMed ID: 8307496
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
Husain A; Sabbatini P; Spriggs D; Fennelly D; Aghajanian C; Barakat R; Curtin J; Venkatraman E; Hoskins W; Markman M
Gynecol Oncol; 1999 Apr; 73(1):96-101. PubMed ID: 10094887
[TBL] [Abstract][Full Text] [Related]
15. Celsite port and catheter as an intraperitoneal access device in the treatment of ovarian cancer.
Topuz E; Salihoglu Y; Aydiner A; Saip P; Tas F; Sozen T; Berkman S; Bengisu E
J Surg Oncol; 2000 Jul; 74(3):223-6. PubMed ID: 10951423
[TBL] [Abstract][Full Text] [Related]
16. Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies.
Kehoe SM; Williams NL; Yakubu R; Levine DA; Chi DS; Sabbatini PJ; Aghajanian CA; Barakat RR; Abu-Rustum NR
Gynecol Oncol; 2009 May; 113(2):228-32. PubMed ID: 19254808
[TBL] [Abstract][Full Text] [Related]
17. [Intraperitoneal chemotherapy through implantable injection port in patients with advanced ovarian (or tubal) carcinoma].
Ryuko K; Iwanari O; Moriyama M; Moriyama M; Nakayama S; Miyako J; Kitao M
Gan To Kagaku Ryoho; 1991 Aug; 18(11):2052-7. PubMed ID: 1877848
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
19. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
Malmström H; Rasmussen S; Simonsen E
Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
